Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Palisade

The New Hyundai Palisade Is Slightly More Expensive

The 2026 Hyundai Palisade costs $1,735 more to start than the 2025 model. The good news is that the price increase coincides with a complete redesign of the automaker's beloved three-row crossover: The new Palisade is longer, lovelier, and has a completely revamped cabin.

Motor1

Elon Musk "concerned" by ChatGPT ignoring 7 shutdown commands in a row during this controlled test of OpenAI's o3 AI model

A new report shows OpenAI's latest AI model, o3, blatantly ignoring instructions to turn itself off in a controlled experiment.

Windows Central

OpenAI’s o3 Model Refused to Shut Down, Even When Told To

OpenAI's o3 Model is back in the headlines, but this time, due to the controversy surrounding it. According to the latest test run by an independent

Geekflare

From analysis to the latest developments in health,
read the most diverse news in one place.

Latest OpenAI models ‘sabotaged a shutdown mechanism’ despite commands to the contrary

Researchers observe the latest OpenAI models sabotaging shutdown attempts, despite explicit commands to allow such interruptions.

Tom’s Hardware

Edmunds: The best three-row SUVs of 2023

Three-row SUVs have been a popular choice among car shoppers with large families

The Independent UK

Next-Gen Hyundai Palisade Coming In 2025 With Hybrid Setup: Report

The naturally aspirated 3.8-liter engine could be dropped in favor of a turbo 3.5-liter.

Motor1

Edmunds compares: Honda Pilot vs. Hyundai Palisade

The Honda Pilot and Hyundai Palisade are midsize SUVs with three rows of seating and a reputation for comfort and value

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

2023 Hyundai Palisade Review: Luxe On A Budget

The Palisade Calligraphy packs premium features and high-end styling that puts it near the top of the class.

Motor1

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has approved Bluebird bio’s (NASDAQ:BLUE) lead asset ZYNTEGLO (betibeglogene autotemcel) to treat the underlying genetic cause of beta‑thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions. Bluebird shares traded in a range of $6.13 to $8.18 on a day…

Benzinga

Hyundai Reveals 2023 Palisade Pricing

Hyundai Motor Co (OTC:HYMTF) has released pricing for the new 2023 Palisade SUV, including its new XRT model. The 2023 Palisade has an upscale interior, advanced technologies, new convenience features, and safety content. Palisade will also offer a new, dark-themed, rugged XRT model to complement the existing Santa Fe and Tucson XRT models…

Benzinga

ARWR: Phase 3 PALISADE Study of ARO-APOC3 Underway…

By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.